Business Wire

Key Identity Verification Trends for 2025: Regula's Expert Insights

21.1.2025 14:30:00 CET | Business Wire | Press release

Share

Regula, a global developer of forensic devices and identity verification solutions, unveils its vision for the identity verification (IDV) industry in 2025. As new and persistent threats converge with evolving regulations and user expectations, they bring to life new requests for significant technological advancements in IDV.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121753818/en/

Regula's experts share their insights into how identity verification will evolve in 2025 (Graphic: Regula)

Threats shaping the IDV landscape

The rise in identity fraud over the past two years has significantly impacted all industries, especially Finance, Banking, FinTech, and Crypto. With deepfakes threatening every second company around the world, businesses won’t be able to stand out without liveness checks, both for biometrics and documents. However, organizations can’t blindly rely on this method as-is. They will have to introduce signal source control viahardware-enabled solutions. With deepfakes being so deeply realistic now, humans often fail to distinguish between what is fake and what is real. That is why checking signal source integrity is crucial, as it helps ensure that no injection is done during the video session within the IDV process.

Also, businesses will further reinforce their biometric verification methods, such as facial recognition, fingerprint scanning, and voice identification, as they add additional defense.

Interestingly, traditional threats like fake IDs and synthetic fraud still account for the majority of identity fraud attempts. This highlights the need for businesses to balance preparing for sophisticated future attacks with addressing the more prevalent threats of today.

Regulations and user expectations: Growing demand and pressure

The IDV landscape is evolving due to stricter laws, rising user expectations, and new workforce demands. Governments are enforcing tighter age verification to protect minors and regulate restricted services. This will be driving further technologies like biometric age estimation.

Users seek fast, personalized IDV solutions, while businesses require flexible systems. So, the IDV industry will continue developing toward user-centric design, where convenience and personalization are prioritized.

Additionally, a new IDV user category is emerging: the workforce. In the era of remote and hybrid work, identity verification for employees is critical to prevent fraud, such as fake identities and ghost employees.

Technological shifts

The evolving challenges of fraud, compliance, and user demands are driving advancements in IDV technologies and the adoption of new digital identity documentslike the Digital Travel Credential (DTC), mobile driver’s licenses (mDLs), digital identity, etc.

To ensure more efficient fraud prevention, identity verification will extend beyond traditional document and biometric checks to include additional methods, such as direct validation against governments’ or issuing authorities’ databases. Also, IDV technologies will be more deeply integrated with other IT solutions deployed in organizations to create secure ecosystems.

Journey Time Orchestration (JTO) is gaining traction, offering a dynamic platform approach to managing identity tasks across the user journey by unifying biometrics, passwords, and third-party systems to balance security and convenience.

Last but not least, AI and ML technologies will be gaining momentum in identity verification. They have been used in IDV solutions for some time already, but their influence will become more tangible as AI-generated fraud evolves into a very significant threat to businesses worldwide.

“The identity verification industry is driven by the multiple forces of advanced threats, rising user demands, tightening regulation, and technological advancements. As we move into 2025, the challenge will be to create solutions that not only address sophisticated fraud but also prioritize user convenience and regulatory compliance,” said Ihar Kliashchou, Chief Technology Officer at Regula.

To get more insights on the trends that will shape IDV in the coming year, read our blog article.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121753818/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye